High-dose plasmid-mediated VEGF gene transfer is safe in patients with severe ischemic heart disease (Genesis-I). A phase I, open-label, two-year follow-up trial-Reference-Cited by-同舟云学术

High-dose plasmid-mediated VEGF gene transfer is safe in patients with severe ischemic heart disease (Genesis-I). A phase I, open-label, two-year follow-up trial

Published:2013-06-05 Issue:6 Volume:82 Page:899-906
ISSN:1522-1946
Container-title:Catheterization and Cardiovascular Interventions
language:en
Short-container-title:Cathet. Cardiovasc. Intervent.

Author:

Favaloro Liliana¹,Diez Mirta¹,Mendiz Oscar¹,Janavel Gustavo Vera²³,Valdivieso León¹,Ratto Roxana¹,Garelli Guillermo³,Salmo Fabián¹,Criscuolo Marcelo³,Bercovich Andrés³,Crottogini Alberto²

Affiliation:

1. Favaloro Foundation University Hospital; Buenos Aires Argentina

2. Department of Physiology; Favaloro University; Buenos Aires Argentina

3. Bio Sidus; Buenos Aires Argentina

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ccd.24555/fullpdf

Reference24 articles.

1. Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia;Vale;Circulation,2001